|Table of Contents|

One case report of advanced colon cancer treated with radiotherapy combined with Keytruda,GM-CSF and literature review

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 04
Page:
623-626
Research Field:
Publishing date:

Info

Title:
One case report of advanced colon cancer treated with radiotherapy combined with Keytruda,GM-CSF and literature review
Author(s):
Huang Shenglan; Yao Weirong; Zeng Lin; Wan Huiping
Department of Oncology，Jiangxi Provincial People's Hospital，Jiangxi Nanchang 330006，China.
Keywords:
colon cancer; radiotherapy; Keytruda; GM-CSF
PACS:
R735.3+5
DOI:
10.3969/j.issn.1672-4992.2019.04.020
Abstract:
Objective:To discuss the effect and adverse reactions of radiotherapy combined with Keytruda and GM-CSF for advanced colon cancer，and to improve the understanding of radiotherapy combined immunotherapy for clinicians．Methods：The authors describe a male patient of advanced colon cancer with bone and multiple-subcutaneous metastasis who was not sensitive to targeted therapy and refused to chemotherapy.To relieve the pain of lumbar spine and prevent the rupture of the subcutaneous metastasis,we gave radiotherapy to lumbar spine and two subcutaneous metastasis on the right side of the abdominal wall and left thigh (diameter is about 2.5 cm and 3 cm),and subcutaneous injected GM-CSF (200 μg qd) to the right side metastasis of the abdominal wall,at the same time giving Keytruda (100 mg ivgtt d1) treatment.We report the disease evolution and outcome after treatment，and review the related literature．Results：After the treatment,the subcutaneous metastasis was gradually reduced,and the pain of the lumbar spine relieved,but the platelets declined rapidly and irreversibly．Conclusion:The effective of radiotherapy combined with Keytruda and GM-CSF is significant,but we need pay more attention to immune related adverse reaction.

References:

［1］Hersey P，Gowrishankar K.Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma［J］.Future Oncol，2015，11(1):133-140.
［2］Van Limbergen EJ,De Ruysscher DK,Olivo Pimentel V,et al.Combining radiotherapy with immunotherapy:the past,the present and the future［J］.Br J Radiol,2017,90:20170157.
［3］Homet Moreno B，Ribas A.Anti-programmed cell death protein-1/ligand-1 therapy in different cancers［J］.Br J Cancer，2015，112(9):1421-1427.
［4］Lin H,Wei S,Hurt EM,et al．Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression ［J］.J Clin Invest，2018，128(2):805-815.
［5］Reck M，Rodriguez-Abreu D，Robinson AG，et al.Pembro-lizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer［J］.N Engl J Med，2016，375(19):1823-1833.
［6］Luke JJ,Lemons JM,Karrison TG，et al.Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors［J］.J Clin Oncol，2018，1(36):61-67.
［7］Fiorica F,Belluomini L,Stefanelli A，et al.Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients:Efficacy and safety of combination［J］.Am J Clin Oncol,2018,41(1):46-52.
［8］Wang X，Schoenhals JE，Li A，et al.Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy ［J］.Cancer Res，2017，77(4):839-850.
［9］Inaba K，Inaba M，Romani N，et al.Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte-macrophage colony-stimulating factor［J］.J Exp Med，1992，176(6):1693-1702.
［10］Borrello I，Pardoll D.GM-CSF-based cellular vaccines:a review of the clinical experience［J］.Cytokine Growth Factor Rev，2002，13(2):185-193.
［11］Golden EB,Chhabra A,Chachoua A,et al.Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours:a proof-of-principle trial［J］.Lancet Oncol，2015,16(7):795-803.
［12］de Filette J，Jansen Y，Schreuer M，et al.Incidence of Thyroid-related adverse events in melanoma patients treated with pembrolizumab［J］.J Clin Endocrinol Metab，2016，101(11):4431-4439.
［13］Lisberg A,Tucker DA,Goldman JW，et al.Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center［J］.Cancer Immunol Res，2018，6(3)：1-7.
［14］Khunger M,Jain P,Rakshit S，et al.Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer:A systematic review and Meta-analysis［J］.Clin Lung Cancer，2017，17(6):378-391.
［15］Herbst RS，Baas P，Kim DW，et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial［J］.Lancet，2016，387(10027):1540-1550.
［16］Garon EB，Rizvi NA，Hui R，et al.Pembrolizumab for the treatment of non-small-cell lung cancer［J］.N Engl J Med，2015，372(21):2018-2028.
［17］Naidoo J，Page DB，Li BT，et al.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies［J］.Ann Oncol，2016，27(7):1362.
［18］HG Hubbeling,EF Schapira,NK Horick，et al.Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer［J］.J Thorac Oncol,2018，13(4):550-558.
［19］Medina PJ，Adams VR.PD-1 pathway inhibitors:Immuno-oncology agents for restoring antitumor immune responses［J］.Pharmacotherapy，2016，36(3):317-334.
［20］Laubli H，Balmelli C，Bossard M，et al.Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma［J］.J Immunother Cancer，2015，3:11.
［21］Tarrio ML，Grabie N，Bu DX，et al.PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis［J］.J Immunol，2012，188(10):4876-4884.
［22］Wu Z,Lai L,Li M,et al.Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer:A case report［J］.Medicine,2017，96(51):31-36.

Memo

Memo:
-
Last Update: 1900-01-01